The U.S. Food and Drug Administration (FDA) initiated a pilot program to accelerate regulatory review for generic drugs manufactured and tested entirely with domestically sourced active pharmaceutical ingredients (APIs). This effort aims to incentivize reshoring of pharmaceutical production, enhance supply chain security, and reduce dependence on foreign manufacturing. The program supports the Trump administration's strategy to bolster domestic drug production through faster approval processes, increased inspections of foreign plants, and economic incentives. It represents a significant policy shift designed to safeguard access to affordable generic medicines and strengthen the resilience of the U.S. pharmaceutical supply chain.